Immunovaccine Inc.


By |


  • Advance cancer immune therapies designed to maintain patients in remission and improve survival
  • Develop differentiated infectious disease vaccines to address unmet medical threats
  • Leverage DepoVax as a potent and flexible product enabling platform through technology licenses and partnerships

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax(TM) platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.

This impressive collection of assets positions Immunovaccine with an advantageous growth strategy that leverages the unique attributes of DepoVax™ through the development of high-value internal vaccine candidates balanced with the upside of collaborative program advancement.

For Immunovaccine's latest Corporate Presentation, please click here.

For Immunovaccine's latest Fact Sheet, please click here.

Click to sign up for Immunovaccine Press Releases and Newsletters

DepoVax™ Platform

The cornerstone of all vaccine development efforts at Immunovaccine is the company’s DepoVax™ vaccine adjuvanting platform. DepoVax™ is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. The result is a strong, specific and sustained immune response with the capability for single-dose effectiveness.

The DepoVax™ platform possesses impressive flexibility, allowing it to work with a broad range of target antigens in various therapeutic applications. The technology is also commercially scalable, with potential for years of stability and ease of use in the clinic.

To date, DepoVax™ has served as the basis for Immunovaccine’s two clinical-stage cancer immunotherapies, as well as a number of partnered vaccine programs spanning infectious diseases, bio-terrorism, addiction medicine and animal health. These collaborators include many leaders in their respective areas of focus including the National Institutes of Health and Zoetis (formerly Pfizer Animal Health).

The graphic below illustrates DepoVax's ability to efficiently attract antigen presenting cells and allow for the controlled uptake of the antigen and adjuvant.

DepoVax Advantages & Applications

Overall Advantages:
Fast, strong and long-lasting immune responses

  • Humoral and/or cellular response possible
  • Compatible with different antigens
  • Stable formulation: long-term storage at ambient temperatures if necessary
  • Easy to re-suspend and administer

DepoVax™ in Cancer:

Maintain remission and combat micro-metastases

  • Provides strong and sustained polyfunctional T cell responses
  • Specifically targets tumor cells

DepoVax™ in Infectious Disease:

Rapid and robust immune response sufficient for disease protection

  • Rapid, durable humoral immune response
  • Single-dose capability – key for pandemic usage


Frederic Ors
Chief Executive Officer

Mr. Frederic Ors brings over 17 years of experience in the biopharmaceutical industry, having served in a number of management roles encompassing business development, intellectual property, strategic planning, pre-marketing and communication. As Chief Business Officer he is responsible for developing business alliances, license arrangements, and partnering opportunities with pharmaceutical companies and government agencies. Before joining Immunovaccine, Frederic spent 14 years at Medicago serving in many roles of increasing responsibility and most recently as Vice President of Business development and Strategic Planning. He has been an integral part of Medicago’s success including securing more than $300M in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts and the $357M deal acquisition by Mitsubishi Pharma in 2013.

He also serves as the second Vice-Chair of the Vaccine Industry Committee of Biotech Canada. Prior to Medicago, he was licensing manager at the University Paris VII-Denis Diderot, one of the largest science and medical University in France. He has a B.Sc. degree in Biology and a Master degree in Management from the University of Angers (France).

Kimberly Stephens
Chief Financial Officer

Ms. Kimberly Stephens is a Chartered Accountant with more than 15 years of financial management experience across several industries. In her current position as Chief Financial Officer of Immunovaccine Inc., Ms. Stephens works effectively with the executive team and Board of Directors and is responsible for producing quarterly and annual financial statements and reporting, budgeting and cash flow projections, analysis, evaluation, and planning related to business activities, strategic alliances, and financing activities. Her past roles include Director of Finance for a Canadian subsidiary of an international company, Germanischer Lloyd, Director of Finance for SolutionInc, and Audit Manager in the Assurance and Advisory group of PricewaterhouseCoopers.

Ms. Stephens is also an avid volunteer, holding positions as director and treasurer of BioNova, Nova Scotia Life Sciences Association, and was the Chair of the Board of Directors for Habitat for Humanity Nova Scotia (2014 - 2016). She also volunteers with the Big Brothers Big Sisters of Greater Halifax.

Rita Nigam, PhD
Vice President, Clinical Research

Dr. Nigam manages the implementation and progress of clinical programs. Prior to joining Immunovaccine in 2009, she developed and managed trials in oncology and cardiovascular programs in the US, Canada and Europe. During a 14-year career at Inex Pharmaceuticals, Pharmacia & Upjohn and SmithKline Beecham, she has led multifunctional teams and optimized the work of CROs, legal firms and other external vendors, resulting in the completion of timely and cost-effective clinical trials. She has managed up to $30M clinical operating budgets. Dr. Nigam also serves as a member of the Scientific Advisory Committee for Soricimed Biopharma Inc. She received her Ph.D. in Pharmacology and Toxicology from Queen’s University, and her undergraduate degree in Biochemistry from Mount Allison University.

Leeladhar Sammatur
Vice President, Product Development & Manufacturing

Mr. Sammatur is responsible for the chemistry, manufacturing and control operations of our DepoVaxTM- based vaccines. He has more than 19 years of experience in vaccine product development from conceptualization to commercialization. He joined Immunovaccine in 2007 as Head Scientist, Analytical Development and was promoted to his current role of Director, Product Development in 2010. His work encompasses formulation/process development, production at contract sites, supply chain management, and analytical development/operations for Immunovaccine’s DepoVaxTM-based investigational products. Prior to joining Immunovaccine, Mr. Sammatur worked at GSK, Novartis, Bharat Biotech and Uni-Sankyo in various capacities.

Mr. Sammatur is a member of the American Association of Pharmaceutical Scientists, the American Chemical Society and the Drug Information Association. He received his Masters degree in Biochemistry from Sri KrishnaDeveraya University.

Marianne Stanford, PhD
Vice President, Research

Dr. Stanford oversees all preclinical research activities in cancer immunotherapies and infectious disease vaccines. She also serves as adjunct professor in Microbiology and Immunology at Dalhousie University; as a member of the Vaccine Discovery group of the Canadian Centre for Vaccinology, and as an Associate Member of the Beatrice Hunter Cancer Research Institute. Before joining the company in 2010, Dr. Stanford conducted her postdoctoral training at the Robarts Research Institute and at the Ottawa Hospital Research Institute, focusing her research on the use of viruses in the development of novel cancer treatments. She received her BSc and MSc from Memorial University of Newfoundland and her PhD from Dalhousie University.

In her spare time, Dr. Stanford is involved in science outreach and policy, volunteering with programs such as Let’s Talk Science, the CIHR Synapse program, Science M@tters and the National Science and Technology Museum biotechnology lecture series. She is the former Chair of the Canadian Association of Postdoctoral Scholars.

Vanessa Lucien
Director of Quality Assurance

Ms. Lucien has extensive knowledge in Quality and Regulatory Affairs with over 15 years of experience. As a consultant, she conducts regulatory audits and training helping ensure that each company is in compliance with global legal requirements and to alleviate problems and enhance strengths within each department. Her regulatory expertise includes FDA, EMeA, Health Canada, ICH and ISO. Ms. Lucien's career in healthcare began as a research analyst in immunochemistry. Since then, she has moved on to serve many key positions and consultant for some of the best companies in the pharmaceutical, medical device, and biotechnology industry. She has provided guidance in regulatory compliance, research and development, product commercialization strategies, operational, project and contract management.

For more information visit

In the interest of full disclosure, we call the reader's attention to the fact that, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

Immunovaccine Inc.


Immunovaccine is a biotechnology company focused on advancing cancer therapies and infectious disease vaccines based on its proprietary products and DepoVax™ platform

Contact Information

Main Phone: +1 902 492-1819
Address: 1344 Summer Street
Address 2: Suite 412
State: NS
City / Town: Halifax
Country: CAN
Postal Code: B3H 0A8

Issuer Information

Exchange: TSX
CEO: Frederic Ors
Employees: 25
Issuer Type: CS - Common Stock
Sector/Industry: Healthcare
NAICS: Pharmaceutical P
$ 1.36 $ 0. (0.00%)
Last Price 1.36 Change $ 0. Change % 0.00 Tick N/A
Bid 1.36 Bid Size 600.00 Ask 1.37 Ask Size 14,000.00
Open 1.37 High 1.38 Low 1.35 Prev Close 1.36
Last Trade Volume 554,845 52 Wk Hi 1.40 52 Wk Low 0.51
Market Cap 161.8 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 118,946,971.00 EPS (TTM) -0.08 PE Ratio N/A Exchange TSX
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 3 3 3 3
Low Target Price Estimate 1.85 1.85 1.85 1.85
Mean Target Price Estimate 2.43 2.43 2.43 2.43
Standard Deviation 0.81 0.81 0.81 0.81
Date of Most Recent Estimate 07/06/16 07/06/16 07/06/16 07/06/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 0 1
Moderate Buy 0 0 0 0
Hold 1 1 1 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.65 1.65 2.3 1